Trading Signals: ABBV Stock Price Prediction and Forecast (Mon. Mar. 17, 2014 - Fri. Dec. 22, 2023)(AbbVie Inc.)
| ABBV latest price $88.6300 (1.14%) ($87.2600 - $89.1900) on Fri. Nov. 15, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 1.33% (three month average) | RSI | 89 | Latest Price | $88.6300(1.14%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ABBV advances 0.8% a day on average for past five trading days. | Weekly Trend | ABBV advances 4.6% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support ABBV advance at 0% a week (0% probability) XLV(63%) SPLV(53%) VYM(53%) DIA(52%) IVE(51%) | Factors Impacting ABBV price | ABBV will decline at least -0.665% in a week (0% probabilities). VIXM(-36%) VXX(-15%) TLT(-15%) IGOV(-4%) UUP(-0%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -0.665% (StdDev 1.33%) | Hourly BBV | 0 () | Intraday Trend | 0.5% | | | |
|
5 Day Moving Average | $87(1.87%) | 10 Day Moving Average | $85.06(4.2%) | 20 Day Moving Average | $81.89(8.23%) | To recent high | 0% | To recent low | 40.7% | Market Cap | $156.368b | | | | AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. |